Femasys’ (FEMY) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Femasys (NASDAQ:FEMY) in a research note published on Tuesday,Benzinga reports. HC Wainwright currently has a $12.00 target price on the stock.

Separately, Chardan Capital cut their target price on Femasys from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th.

Femasys Stock Performance

Shares of FEMY opened at $1.25 on Tuesday. The business’s fifty day moving average price is $1.13 and its 200 day moving average price is $1.12. Femasys has a 12-month low of $0.86 and a 12-month high of $2.40. The stock has a market capitalization of $28.63 million, a PE ratio of -1.54 and a beta of -2.81. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.94 and a quick ratio of 3.26.

Femasys (NASDAQ:FEMY) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.04). The firm had revenue of $0.55 million for the quarter, compared to the consensus estimate of $0.40 million. Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%. Equities research analysts forecast that Femasys will post -0.84 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Virtu Financial LLC purchased a new position in Femasys in the 4th quarter worth about $25,000. Aljian Capital Management LLC acquired a new stake in shares of Femasys during the 3rd quarter valued at about $27,000. XTX Topco Ltd lifted its holdings in shares of Femasys by 123.9% during the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after buying an additional 18,004 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Femasys by 9.2% during the 3rd quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock valued at $229,000 after buying an additional 17,473 shares during the last quarter. 65.27% of the stock is owned by institutional investors and hedge funds.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.